Selecta Biosciences and JDRf have extended their joint research collaboration and added Sanofi as a partner in support of their program to develop immunotherapy for the treatment and prevention of the underlying cause of type 1 diabetes.  This ground breaking therapy is designed to reset the immune system and restore tolerance to substances (antigens) that cause the immune attacks on insulin-producing cells in the pancreas.

For the full article, click HERE.